

1 **Implementing an antibiogram profile to aid rational antimicrobial therapy and**
2 **improving infection prevention in an urban hospital in The Gambia; strategies and**
3 **lessons for low income and middle-income countries.**

4

5 **Authors:**

6 Saffiatou Darboe¹, Ruel Mirasol², Babapelumi Adejuyigbe³, Abdul Khalie Muhammad¹,
7 Behzad Nadjm^{1,4}, Annabelle de St Maurice⁵, Tiffany L. Dogan⁶, Buntung Ceesay¹, Solomon
8 Umukoro¹, Uduak Okomo¹, Davis Nwakanma¹, Anna Roca¹, Ousman Secka¹, Karen Forrest¹
9 and Omai B. Garner² (on behalf of MRCG/UCLA collaborative working group)

10

11 **Affiliations**

12 1. Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical
13 Medicine

14 2. Department of Pathology and Laboratory Medicine, University of California Los Angeles,
15 Los Angeles, California, USA

16 3. David Geffen School of Medicine, University of California, Los Angeles, Los Angeles,
17 California, UCLA

18 4. University College London Hospital NHS Foundation Trust, London, UK

19 5. Department of Pediatrics, Division of Infectious Diseases, David Geffen School of
20 Medicine, UCLA

21 6. Department of Clinical Epidemiology and Infection Prevention, University of California,
22 Los Angeles, California, UCLA Health

23

24 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Corresponding author:

25 Saffiatou Darboe

26 Medical Research Council Unit The Gambia at London School of Hygiene and Tropical

27 Medicine, P.O Box 273 Banjul, The Gambia.

28 email: Saffiatou.Darboe@lshtm.ac.uk

29

30 **Alternative Corresponding Author**

31 Dr Omai Garner.

32 ogarner@mednet.ucla.edu

33

34 **Running title:**

35 Developing and implementing an antibiogram profile in The Gambia

36

37 **Key words:**

38 Cumulative antibiogram, antimicrobial resistance (AMR), Infection prevention and control

39 (IPC), low- and middle-income countries (LMICs), *Escherichia coli* (*E. coli*), *Staphylococcus*

40 *aureus* (*S. aureus*), *Klebsiella pneumoniae* (*K. pneumoniae*) bacteraemia, urinary tract

41 infection (UTI)

42

43 **Abstract:**

44 **Background:** Diagnostic microbiological capabilities remain a challenge in low- and middle-
45 income countries resulting in major gaps. The global antimicrobial resistance burden has
46 necessitated use of appropriate prescribing to curb the menace. This study highlights the
47 process used to develop an antibiogram to monitor resistance at a secondary-level health
48 facility to aid empirical clinical decision making.

49 **Methods:** This retrospective cross-sectional descriptive study used 3 years of cumulative data
50 at the Medical Research Council Unit The Gambia from January 2016 to December 2018.
51 Phenotypic data was manually imputed into WHONET and the cumulative antibiogram
52 constructed using standardised methodologies according to CLSI M39-A4 guidelines.
53 Pathogens were identified by standard microbiological methods and antimicrobial
54 susceptibility testing was performed using Kirby-Bauer disc diffusion method according to
55 CLSI M100 guidelines.

56 **Results:** A total of 14776 non-duplicate samples (blood cultures n=4382, urines n=4914, other
57 miscellaneous swabs and aspirates n=2821 and n=390 respectively, sputa n=334, stools
58 n=1463, CSF 353 and other samples n= 119) were processed of which 1163 (7.9%) were
59 positive for clinically significant pathogens. Among the 1163 pathogens, *E. coli* (n= 315) *S.*
60 *aureus* (n=232), and *K. pneumoniae* (n=96) were the leading cause of disease Overall, the
61 susceptibility for *E. coli* and *K. pneumoniae* from all samples were: trimethoprim-
62 sulfamethoxazole (17% and 28%), tetracycline (26% and 33%), gentamicin (72% and 46%),
63 chloramphenicol (76 and 60%), and ciprofloxacin (69% and 59%), amoxicillin/clavulanic
64 (77% and 54%) respectively. Extended spectrum beta-lactamase resistance was present in 23%
65 (71/315) vs 35% (34/96) respectively. *S. aureus* susceptibility for methicillin was 99%.

66 **Conclusion:** This antibiogram has confirmed susceptibility to commonly used antimicrobials
67 was higher for *E. coli* than *K. pneumoniae* with high ESBL resistance warranting surveillance.
68 An alternative aminoglycoside with better sensitivity such as amikacin might be relevant
69 although this was not tested and that cloxacillin remains a drug of choice for the Staphylococci.

70 **Introduction:**

71 Antimicrobial resistance (AMR) is recognised as a global health threat requiring appropriate
72 containment strategies with sub-Saharan Africa (sSA) disproportionately affected [1,2].
73 Multiple factors transcending disciplines contribute to the development of AMR, with
74 inappropriate use of antibiotics regarded as a major contributing factor according to the report
75 by the WHO Global Action Plan on antimicrobial resistance [3]. Surveillance is key in
76 understanding the epidemiology of AMR to inform appropriate public health intervention and
77 control. Containment strategies including monitoring antibiotic usage, monitoring resistance
78 patterns, using appropriate guidelines for treatment, and establishing effective infection
79 prevention and control (IPC) are essential. Thus, multistakeholder collaboration to combat
80 AMR is required. Active surveillance is paramount in monitoring resistance trends and can be
81 an effective, data driven strategy for evidence-based decision making [4].

82 The cumulative antibiogram periodically summarises a healthcare facility's antimicrobial
83 susceptibility profiles for public health surveillance to identify changes in trends and aid
84 clinicians in making informed empiric therapeutic choices relative to local context [5].
85 Furthermore, antibiograms are useful in detecting potential infectious disease outbreaks. The
86 use of such aggregate data on local or regional resistance trends is fundamental to discern
87 differences and changes in patterns for appropriate selection of antimicrobials for rational use
88 and epidemiological surveillance [1,6]. Thus, diagnostics remain key in combating AMR.
89 However, in low and middle income countries (LMIC), major gaps exist ranging from limited
90 expertise, infrastructure, investment and lack of institutional microbiologic diagnostic
91 capabilities [7,8]. In addition, many countries in sub-Saharan Africa have not prioritized AMR
92 preparedness and implementation of the global action plan to tackle AMR [9,10]. Furthermore,
93 IPC measures to reduce hospital associated infections and antimicrobial resistance surveillance
94 are fundamental for an integrated health system strengthening approach. The understanding of

95 the clinical implications of resistance patterns and interpretation of an antibiogram is
96 paramount for clinical decision making. Thus, the diagnostic microbiology lab must ensure that
97 the antibiogram is generated in collaboration with physicians, pharmacists, and other infectious
98 diseases professionals for improved antimicrobial stewardship [11]. Additionally, antibiogram
99 data must be generated from quality-assured clinical diagnostic microbiology laboratories
100 using guidelines such as the Clinical Laboratory Standards Institute (CLSI) M39-A4 consensus
101 document [12] to ensure reliability for better patient outcomes.

102 Considering this, the Medical Research Council Unit The Gambia at LSTHM
103 (MRCGatLSHTM) and University of California, Los Angeles (UCLA) formed a working
104 group to support microbiological diagnostic capabilities and implementation of an antibiogram
105 to aid empiric therapy and IPC to improve antimicrobial stewardship. This project has provided
106 evidence for the feasibility of harnessing collaborative technical support for implementing
107 AMR stewardship in a sub-Saharan African country.

108 **Methods and Materials:**

109 **Study design and setting:**

110 This study was cross-sectional descriptive analysis of the cumulative antibiogram over a period
111 of three years (January 2016 to December 2018), using data from the Clinical Microbiology
112 Laboratory at the Clinical Services Department (CSD) of the MRCG at LSHTM in The
113 Gambia. A multidisciplinary team of microbiologists, physicians, epidemiologists, and IPC
114 specialists across the collaborating institutions met over several months to review available
115 data.

116 The Gambia is the smallest mainland African country in West Africa with a population of 2.1
117 million with high malnutrition and decreasing malaria incidence [13–15].

118 The CSD has a 42-bed capacity ward and an Outpatient Department seeing approximately
119 50,000 adult and paediatric patients annually. The CSD provides primary and secondary-level
120 care to sick individuals from the surrounding population with complicated cases referred to the
121 main tertiary government hospitals. No surgical departments, obstetrics, or Intensive Care
122 Units are present with limited neonatal admissions. It is the only facility in the Gambia with
123 consistent routine microbiological testing capabilities for patients with suspected invasive
124 infections.

125 **Microbiological procedures**

126 Samples were processed in the diagnostic microbiology laboratory, which is both Good
127 Clinical Laboratory Practice (GCLP; 2010) certified and ISO15189 (2015) accredited.
128 Standard microbiological processing of samples and identification procedures were regularly
129 performed according to standard microbiological protocols. Blood culture samples were
130 routinely collected in BD Bactec aerobic and anaerobic adult and paediatric bottles
131 respectively. Positive bottles were cultured on blood, chocolate and MacConkey agar plates
132 and drops put on microscopic slides for Gram staining. Growth on plates were further

133 characterised and identified using biochemical reagents. Pathogens considered contaminants
134 such as coagulase negative staph, isolated >1 time and confirmed causative agents for infective
135 endocarditis (IE) were considered. The Duke criteria for diagnosing infective endocarditis were
136 used to determine pathogenicity of the viridans group Strep isolates. Blood and cerebrospinal
137 fluid (CSF) samples are routinely collected for bacterial culture from patients presenting with
138 suspected sepsis and meningitis, respectively. Microbiological data is considered community
139 acquired as samples are collected upon presentation and long stays are rare. In addition, first
140 isolate for patient was considered for analysis. Data is reported and stored in a local electronic
141 medical record system (EMRS). Selective reporting of antimicrobials is yet to be introduced
142 and specimens were anonymised for confidentiality prior to analysis.

143 Urine samples were considered clinically significant when growth $>10^5$ of a single organism.
144 Urines were primarily cultured on cysteine lactose electrolyte deficient (CLED) and incubated
145 overnight at 37°C, followed by appropriate pathogen identification if growth was $> 10^5$ CFUs.
146 Other samples were cultured on appropriate agar plates such as blood, chocolate, MacConkey,
147 sabouraud dextrose and Thayer-martin agar plates as indicated. Isolates were identified using
148 appropriate biochemical tests; *Enterobacteriales* were identified using BioMerieux API20E,
149 other non-enteric Gram-negative were identified using API20NE. *Staphylococcus aureus* (*S.*
150 *aureus*) were identified using Staphaurex Plus and mannitol salt agar testing. *Streptococcus*
151 *pneumoniae* (*S. pneumoniae*) was confirmed using optochin disc, with confirmatory testing
152 using bile solubility. *Haemophilus influenzae* (*H. influenzae*) was identified using X and V
153 factors and serological testing. In addition, beta-haemolytic group *Streptococci* were identified
154 using Streptex/Wellcogen serological test. Antimicrobial susceptibility patterns were
155 determined by Kirby-Bauer disk diffusion on Mueller-Hinton agar and zone sizes interpreted
156 according to the relevant Clinical Laboratory Standard Institute (CLSI) guidelines on
157 antimicrobial agents [16]. Appropriate American Type Culture Collection (ATCC) controls *E.*

158 *coli* 25922, *P. aeruginosa* 29835, *S. aureus* 25923 and *S. pneumoniae* 49616 were consistently
159 used as quality control organisms for the antibiotic susceptibility testing and reagent
160 performance verification.

161 **Analysis**

162 Data were extracted from the Electronic Medical Record System (EMRS), uploaded into
163 WHONET, cross-checked for unusual susceptibility patterns, verified as per CLSI M39 [12]
164 and cleaned. All pathogens isolated during the period considered as individual infection
165 episodes were included. Isolates from successive cultures from different body sites were
166 reviewed and the first isolate included as per the CLSI guideline. Data was stratified by
167 specimen type for blood and Urine and analysed. Heat maps were generated to visually
168 highlight resistance patterns and bar charts to show differences in organism frequencies among
169 samples. Tables were generated to show cumulative antibiograms for use and implement
170 antimicrobial prescription guideline. [12].

171 **Ethical review and approval**

172 The study is part of an ongoing microbiological improvement project to implement local
173 prescribing guideline and antimicrobial stewardship at the MRCG at LSHTM.

174 **Results:**

175 **Samples and pathogen distribution:**

176 Over the 3-year period, a total of 14,776 different specimens were received and processed
177 (Figure 1, flowchart), of which 1163 clinically significant organisms were isolated. Urine and
178 blood cultures accounted for one-third (n=4914) and (n=4382) of the samples respectively.

179 Results of 182 blood cultures, (4.2%) were considered clinically significant (Figure 2a). The
180 leading cause of bacteraemia were *E. coli* (n=40) and *S. aureus* (n=39) responsible for 22.0%
181 and 21.4% respectively (Figure 2b). This was followed by non-typhoidal *Salmonella* (NTS)
182 (n=16), *S. pneumoniae* (n=15), *Enterococcus* species (n=15), and *Pseudomonas* species other
183 than *P. aeruginosa* (n=10) (Table 1). From urine samples, 9.0% were confirmed clinically
184 relevant (n=442) (Figure 2a). Among the causes of UTI, 55.4% were *E. coli* (n=245) and 12.7%
185 were *K. pneumoniae* (n=56) (Figure 2b) followed by other coliform bacteria (n=31), *Candida*
186 species (n=26), *Enterococcus faecalis* n=16 and *Streptococcus agalactiae* n=14 (Table 2).

187 Out of 2821 swabs, a total of 381 (13.5%) were considered clinically significant. The swabs
188 were further stratified into eye, ear, nose & throat (EENT) n=1628, skin/wound n=1131 and
189 urogenital n=62 (Figure 1). When stratified according to swab type, 1.2% pathogens were
190 recovered from EENT (n=19), 3.2% of pathogens were recovered from skin/wound (n=355)
191 and 11.3% from urogenital swabs (n=7). The leading pathogens from EENT were *H. influenzae*
192 non-type b (n=5), *K. pneumoniae* (n=4) and *S. pneumoniae* (n=4) (Supplementary figure 1).
193 For skin/wound swab, the leading pathogens were *S. aureus* (n=148), *Pseudomonas aeruginosa*
194 (n=39) and *S. pyogenes* (n=38). From urogenital swabs, *S. agalactiae* (4/7) and *N. gonorrhoea*
195 (3/7) were recovered. Among the 390 aspirates, 12.6% (n=49) were considered clinically
196 significant. They were stratified into abscess (n=25) and aspirates from invasive sterile sites
197 (n=365). Pathogenic organisms were recovered from 96% abscesses (24/25) and 6.8% of

198 invasive aspirates (25/365). The organisms from abscesses were 83.3% *S. aureus* (n= 20), one
199 each of *Morganella morganii*, NTS, *Streptococcus* group F and *K. pneumoniae*. Among 25
200 pathogens from invasive sterile aspirates, *Streptococci* species (n=7) and *S. aureus* (n=7) were
201 most prevalent, followed by other coliform bacteria (n=4), two *S. pneumoniae* and two
202 *Pseudomonas* species (Supplementary figure 2). Among 334 sputa samples, 26.0% were
203 positive for a pathogen (n=87). The leading pathogens were *H. influenzae* non-type b n=20
204 (23%) and *K. pneumoniae* n=17 (19.5%) (Figure 2b). Over the time period studied, only (1.7%)
205 of 353 CSF grew pathogens (n=6) of which four were *S. pneumoniae*, one *E. coli* and one
206 *Pseudomonas* species. Among the stool samples, 13 pathogens were isolated of which (n=10)
207 were NTS.

208 Overall, *E. coli* (27.1% of the pathogens) and *S. aureus* (19.9%) and were found to be the
209 leading cause of disease in our setting (Figure 2b) followed by *Klebsiella pneumoniae* 8.3%
210 (n=96), *Pseudomonas aeruginosa* (n=57), other coliform bacteria (n=52), *Streptococcus*
211 *pyogenes* (n=45), *Enterococcus* species (n=43), *Pseudomonas* species other than *aeruginosa*
212 (n=43), *Proteus* species (n=41), *Streptococcus pneumoniae* (n=31) and *Klebsiella* species other
213 than *pneumoniae* (n=30), non-typhoidal *Salmonella* (n=28) and *Streptococcus agalactiae*
214 (n=27) (Figure 2b). *E coli* was prevalent in urine, blood and swabs whilst *S. aureus* was
215 prevalent in swabs, blood and aspirates. In addition, *K. pneumoniae* was prevalent in urine,
216 sputum and swabs.

217 **Susceptibility profiles of pathogens**

218 Susceptibility patterns for the common pathogens found in blood and/or urinary pathogens for
219 various antimicrobials was varied (Table 1 for blood culture and Table 2 for urinary pathogens).
220 The major causative agents for UTI were highly susceptible to nitrofurantoin (94%). Overall,
221 the *Enterobacteriales* (except NTS) susceptibility to ampicillin was 11% for *E. coli* and 44%

222 for *Proteus* species. Susceptibilities to 3rd generation cephalosporins for *E. coli* and *K.*
223 *pneumoniae* were 86% and 54%, for cephamycin 97.8% and 97.9% and for the beta-lactamase
224 inhibitor clavulanic acid 77.2% and 65% respectively. ESBL resistance was present 23%
225 (71/315) vs 35% (34/96) for *E. coli* and *K. pneumoniae* respectively. Susceptibilities to
226 chloramphenicol, ciprofloxacin and gentamicin for *E. coli* were 75.7%, 72.7% and 75.9%
227 respectively. For *K. pneumoniae* 60%, 63.5%, 53.2% and for *S. aureus* 97.3%, 98.9%, 95.2%
228 respectively (Figure 3). Remarkably, susceptibility for methicillin for *S. aureus* was very high
229 99.4% but low for penicillin 20.2%. *S. pneumoniae* and *H. influenzae* were susceptible to
230 penicillin 77.4% and ampicillin 100% respectively but low for trimethoprim-sulfamethoxazole
231 (0%). Penicillin susceptibility for *Enterococcus* was 81.4%. *S. agalactiae* and *S. pyogenes*
232 susceptibilities were 100% susceptible for penicillin but for tetracycline 33.3% and 29.6%
233 respectively. These susceptibility profiles are shown in the heatmap depicting increasing
234 resistance with from purple to red (Figure 3)

235 **Discussion:**

236 This study provides an antibiogram profile from the diagnostic microbiology laboratory for
237 clinical samples over a three-year period in The Gambia to aid in empirical clinical decision
238 making. This is part of a collaborative network between the MRCG, and UCLA set out to
239 improve microbiological laboratory capacity and improve IPC. Diagnostic microbiological
240 capabilities with standardised methodologies and expertise for detection and management of
241 AMR are often scarce in many LMICs [6,17]. The global action plan on antimicrobial
242 resistance highlights inappropriate prescribing as one of the main drivers of AMR [3], thus, the
243 implementation of this antibiogram is paramount in understanding resistance dynamics to aid
244 rational local prescribing. The antibiogram is particularly useful when the infecting organism
245 is known prior to susceptibility patterns. With the global spread of antimicrobial
246 resistance[2,18], it is a useful tool to monitor local changes to provide evidence-base data for
247 local prescribing guidelines. However, it is important that ways of disseminating the
248 information to all prescribers are facilitated for easy access in prescribing areas. It is also
249 important that users are educated in its effective use and effect on patient outcome [19] and
250 thus this study facilitated that in a local hospital.

251 In this study, *E. coli* and *S. aureus* were found to be the most prevalent cause of all disease and
252 in particular bacteraemia. It is important to note that *S. aureus* remains a prevalent cause of
253 bacteraemia [15,20] as seen in other parts of globe [21,22]. However, *E. coli* is for the first
254 time being reported in the top two bacteraemia pathogens, taking over from *S. pneumoniae* as
255 reported previously [15,20]. In addition, it remains the prevalent cause of UTIs. The reduced
256 importance of *S. pneumoniae* as a cause of bacteraemia in The Gambia is attributed to the
257 increasing impact of pneumococcal conjugate vaccines over the years after a higher prevalence
258 of children have been vaccinated [23,24]. The vaccine effectiveness studies done in The
259 Gambia have shown both substantial reduction in incidence of pneumococcal bacteraemia

260 among young children [24] and in pneumonia hospitalisation [25]. Invasive NTS remains a
261 major cause of bacteraemia albeit with low resistance found in this setting. Notwithstanding,
262 the geographical differences noted for NTS serovars and resistance patterns in previous studies
263 ([26,27] warrant advances in surveillance and monitoring to provide information on
264 prescribing.

265 The coagulase negative *Staphylococci* and viridan group *Streptococci* were mainly considered
266 contaminant unless in patients with underlying conditions such as infective endocarditis,
267 malignancy and neutropenia after meeting criteria for clinical relevance [28]. It is particularly
268 important to state that quality improvement to reduce contaminant rates and improved
269 collection techniques to increase yield in blood cultures is also ongoing.

270 The urine samples harboured the most common bacterial isolates with *E. coli*, *K. pneumoniae*
271 and other coliforms as the leading cause of community acquired UTI. Patients were not
272 stratified by age, sex, symptoms or with co-morbidities as this was beyond the scope of this
273 study. A more robust study considering these factors is warranted considering it's a significant
274 cause of morbidity and burden in The Gambia [29,30]. It is important to note that the use of
275 indwelling catheters is uncommon in this setting. However, the overall causes of UTIs in The
276 Gambia are of Gram-negative origin as in other studies [31–33]. *Enterococcus faecalis* and
277 *Streptococcus agalactiae* was also found to cause disease.

278 The susceptibilities for *E. coli* were similar for both disease syndromes except for ciprofloxacin
279 which was comparatively lower for urinary tract strains (69% vs 85%) than for blood strains.
280 This warrants further investigation into the genomic epidemiology of this important invasive
281 pathogen. Although susceptibility profiles for *E. coli* and other *Enterobacterales* remain high
282 except for *K. pneumoniae*, lower susceptibility is reported in this study than previously for
283 ciprofloxacin, gentamicin, chloramphenicol, and 3rd generation cephalosporins [15]. However,

284 the lower ciprofloxacin susceptibility profile seen for *E. coli* in UTI compared to bacteraemia
285 deserves further investigation and characterisation. Multidrug resistance was evident especially
286 for ampicillin, tetracycline and trimethoprim-sulfamethoxazole. Both Gram-negative and
287 Gram-positive pathogens had low susceptibilities profiles for trimethoprim-sulfamethoxazole
288 and tetracycline making these ineffective in our setting. It is worth highlighting that
289 carbapenem resistance is yet to be established routinely. Importantly, in the era of the decline
290 of pneumococcal meningitis and bacteraemia ([15,24,25], we continue to find increasing
291 resistance to penicillin in this study highlighting the need for surveillance.

292 The WHO recommended empiric drug of choice for sepsis remain for ampicillin and
293 gentamicin. This data therefore provides evidence for the modification of this combination to
294 include cloxacillin and amakicin. *S. aureus* remains susceptible to cefoxitin, the proxy for
295 methicillin and show that cloxacillin remains effective in our setting as previously described
296 [15,34–36]. Penicillin, tetracycline, and trimethoprim-sulfamethoxazole susceptibility
297 however was low for most pathogens including *S. aureus*. These drugs are widely available to
298 the public and misused due to lack of regulation. The emerging penicillin resistance warrant
299 further surveillance and highlights the need for improved microbiologic diagnostic capabilities
300 and local antibiogram for appropriate antimicrobials. However, implementation of appropriate
301 IPC interventions and adherence to guidelines with supporting diagnostic evidence remains a
302 major challenge in sub-Saharan Africa [37].

303 In the advent of AMR, data on local context could be used to inform therapeutic guidelines and
304 improve prescribing and impact on stewardship. To overcome the challenges of AMR, it is
305 important to employ a combination of strategies including improving sanitation to reduce
306 infections episodes, use of guidelines for standardized diagnostic methodologies, and improved
307 expertise and knowledge in understanding the threat posed by this silent pandemic. In

308 additions, reducing infections through improving hygiene and strengthening IPC in hospitals
309 is a key intervention strategy in curbing the spread of resistance. In resource limited settings
310 where there has been an increase in empiric treatment with WHO ‘reserve’ antibiotics [3], the
311 knowledge and use of a local antibiogram and investing in infection prevention control are
312 paramount for the management of AMR. In addition, the key involvement of the microbiology
313 leads with insight into the clinical relevance of the results generated has added value into this
314 interpretation. It is important that laboratory staff are aware of the public health and clinical
315 significance of their findings [38]. The inclusion and involvement of physicians in the process
316 was useful in understanding of the interpretation of the antibiogram and facilitated
317 implementation in routine prescribing as recommended [39].

318 This study highlights the feasibility of implementing AMR containment strategies to improve
319 prescribing guideline in a LMIC and has provided evidence that multistakeholder collaborative
320 effort could improve antimicrobial stewardships across borders. The implementation of the
321 cumulative antibiogram using standardised methodology for the first time is a great opportunity
322 to further disseminate the knowledge and skills across the entire country. This has important
323 implications for antimicrobial stewardship policy. There are several limitations in this study
324 that may hinder its general applicability. First, although the first isolates for patient was
325 included in the analysis, it did not reveal if sample was collected at point of admission or during
326 admission. Hence, we could not reliably identify a potential hospital associated infection.
327 Second, the data was not stratified by age and risk factors. Thirdly, time of sample collection
328 was not documented. Notwithstanding, this antibiogram data has shown high susceptibility
329 profiles for pathogens of public health significance. We have also demonstrated that
330 engagement and multistakeholder collaboration can be harnessed to solve global challenges
331 such as AMR. We have shown that common antimicrobials are still effective in this setting but
332 importantly, evidence for an improvement in combination therapy is warranted locally.

333 **Funding**

334 This work is supported by the MRCGatLSHTM and the UCLA. The source of funding has no
335 role in the design and writing of the manuscript.

336 **Conflict of interest:**

337 The authors declare no conflict of interest

338 **Acknowledgement:**

339 We thank staff of Clinical Services Department and Clinical Laboratories for their support,
340 comments, and suggestions.

341 **Contributors:**

342 SD, DN, KF and OG designed the study. SD and OG wrote the draft manuscript. SD did the
343 laboratory analysis and cleaned the data; SD, BA, AKM, RM and OG analysed the data
344 prepared the tables and figures; BN and KF provided clinical care to the patients and facilitated
345 implementation of the antibiogram into clinical practice; All authors critically reviewed and
346 contributed to the manuscript.

347

348 * Other members of the MRCG/UCLA collaborative working group:

349 Usman Nurudeen Ikumapayi

350 Rasheed Salaudeen

351 Mamina Bojang

352 Patrick Okot

353 Edwin Kamau

References

- 354 1. WHO. Organization World Health. Global Strategy for Containment of Antimicrobial
355 Resistance. World Heal Organ. 2001;105.
- 356 2. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global
357 burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*.
358 2022;6736(21).
- 359 3. WHO. Global action plan on antimicrobial resistance. World Heal Organ. 2017;1–28.
- 360 4. WHO. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report
361 2021. 2021.
- 362 5. Handler JF, Stelling J et al. Analysis and presentation of cumulative antibiograms: A
363 new consensus guideline from the Clinical and Laboratory Standards Institute. *Clin*
364 *Infect Dis*. 2007;44(6):867–73.
- 365 6. Avdic E, Carroll KC et al. The role of the microbiology laboratory in antimicrobial
366 stewardship programs. *Infect Dis Clin North Am*. 2014;28(2):215–35.
- 367 7. Archibald LK, Reller LB. Clinical microbiology in developing countries. In: *Emerging*
368 *Infectious Diseases*. 2001.
- 369 8. Petti CA, Polage CR, Quinn TC, et al. Laboratory medicine in Africa: A barrier to
370 effective health care. Vol. 42, *Clinical Infectious Diseases*. 2006.
- 371 9. Elton L, Thomason MJ, Tembo J et al. Antimicrobial resistance preparedness in sub-
372 Saharan African countries. *Antimicrob Resist Infect Control*. 2020;9(1).
- 373 10. Iwu CD, Patrick SM. An insight into the implementation of the global action plan on

- 374 antimicrobial resistance in the WHO African region: A roadmap for action. *Int J*
375 *Antimicrob Agents*. 2021;58(4).
- 376 11. Truong WR, Hidayat L, Bolaris MA, Nguyen L, Yamaki J. The antibiogram: key
377 considerations for its development and utilization. *JAC-Antimicrobial Resist*. 2021;3(2).
- 378 12. CLSI. M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility
379 Test Data ; Approved Guideline — Fourth Edition. *Clin Lab Stand Inst*. 2014;(January).
- 380 13. Review TGC. The Gambia Country Review: Key Data. *Gambia Ctry Rev*. 2009;
- 381 14. Ceesay SJ, Casals-Pascual C et al. Continued decline of malaria in The Gambia with
382 implications for elimination. *PLoS One*. 2010;5(8):e12242.
- 383 15. Darboe S, Okomo U et al. Community-acquired Invasive Bacterial Disease in Urban
384 Gambia , 2005 – 2015 : A Hospital-based Surveillance. *Clin Infect Dis*. 2019;69(Suppl
385 2):105–13.
- 386 16. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth
387 Informational Supplement. CLSI Document M100-S25. Clinical and Laboratory
388 Standards Institute. 2015.
- 389 17. Tadesse BT, Ashley EA, et al. Antimicrobial resistance in Africa: A systematic review.
390 *BMC Infect Dis*. 2017;17(616).
- 391 18. van Boeckel T, Pires J et al. Global Trends in Antimicrobial Resistance in Animals in
392 Low- and Middle-income Countries. *Science (80-)*. 2019;365(6459).
- 393 19. Lacy MK, Klutman NE, Horvat RT, Zapantis A. Antibiograms: New NCCLS
394 guidelines, development, and clinical application. *Hosp Pharm*. 2004;39(6):542–53.

- 395 20. Hill PC, Onyeama CO et al. Bacteraemia in patients admitted to an urban hospital in
396 West Africa. *BMC Infect Dis.* 2007;7:2–10.
- 397 21. Laupland KB, Lyytikäinen O et al. The changing epidemiology of *Staphylococcus*
398 *aureus* bloodstream infection: A multinational population-based surveillance study. *Clin*
399 *Microbiol Infect.* 2013;19(5)(5):465–71.
- 400 22. Laupland KB, Gregson DB et al. Burden of community-onset bloodstream infection: A
401 population-based assessment. *Epidemiol Infect.* 2007;
- 402 23. Cutts FT, Zaman SMA et al. Efficacy of nine-valent pneumococcal conjugate vaccine
403 against pneumonia and invasive pneumococcal disease in The Gambia: Randomised,
404 double-blind, placebo-controlled trial. *Lancet.* 2005;
- 405 24. Mackenzie GA, Hill PC et al. Effect of the introduction of pneumococcal conjugate
406 vaccination on invasive pneumococcal disease in The Gambia: a population-based
407 surveillance study. *Lancet Infect Dis.* 2016;16(6):703–11.
- 408 25. Mackenzie GA, Hill PC et al. Impact of the introduction of pneumococcal conjugate
409 vaccination on pneumonia in The Gambia: population-based surveillance and case-
410 control studies. *Lancet Infect Dis.* 2017;17(9)(9):965–73.
- 411 26. Kanteh A, Sesay AK et al. Invasive atypical non-typhoidal *Salmonella* serovars in The
412 Gambia. *Microb Genomics.* 2021;7(11).
- 413 27. Darboe S, Bradbury R et al. Genomic diversity and antimicrobial resistance among non-
414 typhoidal *Salmonella* associated with human disease in The Gambia. *Microb Genomics.*
415 2022;8(3):1–13.
- 416 28. Su TY, Lee MH et al. The clinical impact of patients with bloodstream infection with

- 417 different groups of Viridans group streptococci by using matrix-assisted laser desorption
418 ionization-time of flight mass spectrometry (MALDI-TOF MS). *Med (United States)*.
419 2018;97(50).
- 420 29. Öztürk R, Murt A. Epidemiology of urological infections: a global burden. *World J Urol*.
421 2020;38(11).
- 422 30. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary
423 tract infections. Vol. 11, *Therapeutic Advances in Urology*. 2019.
- 424 31. Uwaezuoke SN, Ndu IK et al. The prevalence and risk of urinary tract infection in
425 malnourished children: A systematic review and meta-Analysis. *BMC Pediatr*.
426 2019;19(1).
- 427 32. Erdem I, Kara Ali R et al. Community-acquired lower urinary tract infections: Etiology,
428 antimicrobial resistance, and treatment results in female patients. *J Glob Infect Dis*.
429 2018;10(3).
- 430 33. Donkor ES, Horlortu PZ et al. Community acquired urinary tract infections among
431 adults in Accra, Ghana. *Infect Drug Resist*. 2019;12.
- 432 34. Darboe S, Dobreniecki S, Jarju S et al. Prevalence of Panton-Valentine Leukocidin
433 (PVL) and Antimicrobial Resistance in Community-Acquired Clinical *Staphylococcus*
434 *aureus* in an Urban Gambian Hospital: A 11-year period retrospective pilot study. *Front*
435 *Cell Infect Microbiol*. 2019;9(170).
- 436 35. Armitage EPEP, Senghore E, Darboe S, Barry M, Camara J, Bah S, et al. High burden
437 and seasonal variation of paediatric scabies and pyoderma prevalence in the Gambia: A
438 cross-sectional study. *PLoS Negl Trop Dis*. 2019;13(10):1–16.

- 439 36. Odotola A, Bottomley C, Zaman SA, Lindsay J, Shah M, Hossain I, et al.
440 Staphylococcus aureus bacteremia in children of rural areas of The Gambia, 2008–2015.
441 Emerg Infect Dis. 2019;25(4).
- 442 37. Bediako-Bowan AAA, Owusu E et al. Antibiotic use in surgical units of selected
443 hospitals in Ghana: A multi-centre point prevalence survey. BMC Public Health.
444 2019;19(1).
- 445 38. El-Azizi M, Mushtaq A et al. Evaluating antibiograms to monitor drug resistance. Emerg
446 Infect Dis. 2005;11(8):1301–2.
- 447 39. Ambretti S, Gagliotti C et al. Reporting epidemiology of antibiotic resistance. Microbiol
448 Medica. 2015;30(2).

449 **Figure legends and tables**

450 Figure 1: Flow chart showing distribution of the different samples

451 Figure 2a: Graph showing total number of samples received against clinically significant
452 pathogens recovered

453 Figure 2b: Bar chart showing proportion of pathogenic organisms by sample type

454 Figure 3: Heatmap showing the intensity of resistance patterns for the different pathogens.

455 Purple depicting susceptibility and increasing resistance shown from yellow to red

456 Supplementary figure 1: Bar chart showing the percentage of pathogens recovered from the
457 various swabs


458 Supplementary figure 2: Bar chart showing the absolute numbers for the pathogens recovered
459 from the various aspirates

460 Table 1: Susceptibility profile for the common blood culture pathogens

461 Table 2: Susceptibility profile for the urine pathogens


Figure 1

Flowchart showing distribution of different samples




462


Figure 2a Graph showing total number of samples received against clinical significant pathogens recovered



463




464



465

Supplementary figure 1


Bar chart showing the pathogen (%) recovered from the sv



466

Supplementary figure 2

Bar chart showing the pathogens numbers recovered from aspira



467

468

469

470

Table 1. Susceptibility profile for the common blood culture pathogens

Organism	NUMBER	% Susceptibility															
		PEN	AMP	SXT	CN	CHL	TET	CIP	CXM	ERY	PB	OX	FOX	CTX	CAZ	VA	AMC
Gram-negatives																	
<i>E. coli</i>	40	Na	13	15	83	85	38	85	38	Na	Na	Na	97	90	88	Na	80
NTS	16*	Na	100	88	94	100	88	100	100	Na	Na	Na	100	100	100	Na	100
<i>Pseudomonas</i> species	10*	Na	Na	22	90	22	63	89	50	Na	Na	Na	NA	Na	100	Na	Na
Gram-positives																	
<i>S. aureus</i>	39	13	Na	69	97	97	74	100	Na	87	Na	100	100	Na	Na	100	Na
<i>S. pneumoniae</i>	15*	80	Na	7	Na	93	67	Na	Na	93	Na	80	Na	Na	Na	100	Na
<i>Enterococcus</i> species	15*	92	92	Na	Na	83	58	83	Na	58	Na	Na	Na	Na	Na	100	Na

471 *Less than the recommended number of 30 isolates

472

473

Table 2. Susceptibility profile for urine pathogens

474

Organism	Number	% Susceptibility																
		PEN	AMP	OB	OX	SXT	CN	TET	F300	CIP	ERY	CXM	CAZ	CTX	FOX	AMC	PB	VA
Gram-negatives																		
<i>E coli</i>	245	Na	11	Na	Na	16	72	26	97	69	Na	78	88	84	98	77	Na	Na
<i>K. pneumoniae</i>	56	Na	0	Na	Na	16	46	33	80	59	Na	29	41	40	96	54	Na	Na
Coliform species	31	Na	7	Na	Na	23	87	38	100	83	Na	74	80	87	87	61	Na	Na
Klebsiella species	14*	Na	0	Na	Na	7	36	57	79	57	Na	36	50	50	100	29	Na	Na
Gram-positives																		
<i>Candida</i> species	26*	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na	Na
<i>Enterococcus</i> species	16*	94	88	Na	Na	Na	Na	13	94	75	81	Na	Na	Na	Na	Na	Na	94
<i>S. agalactiae</i>	14*	100	100	Na	Na	86	Na	7	100	100	100	Na	Na	Na	Na	Na	Na	100
<i>S. aureus</i>	12*	58	Na	100	100	58	100	92	100	100	100	NA	Na	Na	100	Na	Na	100

475 *Less than the recommended number of 30 isolates

476